Schwartz-Jampel syndrome is a rare autosomal recessive disorder characterized by myotonia and skeletal dysplasia. Botulinum toxin A is emerging as a therapeutic option for patients with this syndrome. This study describes the use of botulinum toxin A in 4 children with Schwartz-Jampel syndrome. The response to this therapeutic modality was limited and variable.
Schwartz O., Jampel RSCongenital blepharophimosis associated with a unique generalized myopathy . Arch Ophthalmol. 1962;68:52-57.
2.
Aberfeld DC, Namba T., Vye MV, Grob D.Chondrodystrophic myotonia: report of two cases: myotonic dwarfism, diffuse bone disease, and unusual ocular and facial abnormalities. Arch Neurol. 1970;22:455-462.
3.
Adams RD, Victor M.Principles of Neurology. 6th ed. New York: McGraw-Hill; 1997.
4.
Giedion A., Boltshauser E., Briner J., et al. Heterogeneity in Schwartz-Jampel chondrodystrophic myotonia . Eur J Pediatr. 1997;156:214-223.
5.
Dagoneau N., Scheffer D., Huber C., et al. Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome. Am J Hum Genet. 2004;74:298-305.
6.
Morrison DA, Mellington FB, Hamada S., et al. Schwartz-Jampel syndrome: surgical management of the myotonia-induced blepharospasm and acquired ptosis after failure with botulinum toxin A injections . Ophthal Plast Reconstr Surg. 2006;22:57-59.
7.
Vargel I., Canter HI, Topaloglu H., et al. Results of botulinum toxin: an application to blepharospasm in Schwartz-Jampel syndrome. J Craniofac Surg. 2006;17:656-660.
8.
Squires LA, Prangley J.Neonatal diagnosis of Schwartz-Jampel syndrome with dramatic response to carbamazepine . Pediatr Neurol. 1996;15:172-174.
9.
Topaloglu H. , Serdaroglu A., Okan M., et al. Improvement of myotonia with carbamazepine in three cases with the Schwartz-Jampel syndrome . Neuropediatrics . 1993;24: 232-234.
10.
Spaans F., Wagenmakers A., Saris W., et al. Procainamide therapy, physical performance and energy expenditure in the Schwartz-Jampel syndrome. Neuromuscul Disord. 1991;1:371-374.
11.
Lucci LM, Yen MT, Anderson RL, et al. Orbicularis myectomy with levator advancement in Schwartz-Jampel syndrome. Am J Ophthalmol. 2001;132:799-801.
12.
Viljoen D, Beighton.Schwartz-Jampel syndrome (chondrodystrophic myotonia). J Med Genet. 1992;29:58-62.
13.
Arikawa-Hirasawa E., Le AH, Nishino I., et al. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am J Hum Genet . 2002 ;S70:1368-1375.
14.
Peng HB, Xie H., Rossi SG, et al. Acetylcholinesterase clustering at the neuromuscular junction involves perlecan and dystroglycan. J Cell Biol. 1999;145:911-921.
15.
Stum M., Davoine CS, Vicart S., et al. Spectrum of HSPG2 (perlecan) mutations in patients with Schwartz-Jampel syndrome. Hum Mutat. 2006;27:1082-1091.
16.
Calace P., Cortese G., Piscopo R., et al. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophthalmol. 2003;13:331-336.
17.
Costa J., Espírito-Santo C., Borges A., et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev. 2004:CD004900.
18.
Ortisi E., Henderson HW, Bunce C., Xing W., Collin JRBlepharospasm and hemifacial spasm: a protocol for titration of botulinum toxin dose to the individual patient and for the management of refractory cases. Eye. 2006;20:916-922.
19.
Pang AL, O'Day J.Use of high-dose botulinum A toxin in benign essential blepharospasm: is too high too much?Clin Exp Ophthalmol. 2006;34:441-444.
